Remove companies sierra-oncology-inc
article thumbnail

The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More

Benzinga

Halozyme Buys Specialty Product Company Antares In $960M Deal. Halozyme Therapeutics Inc (NASDAQ: HALO ) will acquire Antares Pharma Inc (NASDAQ: ATRS ) for $5.60 GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Stocks In Focus. per share , valuing Antares at approximately $960 million.

Equity 98
article thumbnail

Sierra Oncology Stock Is Soaring: Here's Why

Benzinga

Sierra Oncology Inc (NASDAQ: SRRA ) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK ) for $55 per share in cash, representing an approximate total equity value of $1.9

Equity 52